financetom
Business
financetom
/
Business
/
Air Products Q4 adjusted EPS beats estimates on cost controls
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Air Products Q4 adjusted EPS beats estimates on cost controls
Nov 6, 2025 3:29 AM

Overview

* Air Products Q4 sales slightly beat analyst expectations

* Adjusted EPS for Q4 beats consensus, reflecting operational excellence

* Fiscal 2025 results impacted by significant charges related to business and asset actions

Outlook

* Air Products expects fiscal 2026 adjusted EPS of $12.85 to $13.15

* Company anticipates fiscal 2026 capital expenditures of approximately $4 bln

* Air Products forecasts Q1 fiscal 2026 adjusted EPS of $2.95 to $3.10

Result Drivers

* VOLUME DECLINE - Lower volumes due to LNG business sale and reduced helium demand impacted results

* COST MANAGEMENT - Productivity improvements partially offset higher fixed-cost inflation and depreciation

* PROJECT PORTFOLIO RATIONALIZATION - Exited various energy transition projects to focus on core industrial gases

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Sales Slight $3.20 $3.18

Beat* bln bln (15

Analysts

)

Q4 Beat $3.39 $3.38

Adjusted (17

EPS Analysts

)

Q4 EPS $0.02

Q4 NET $10.10

INCOME mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the commodity chemicals peer group is "buy"

* Wall Street's median 12-month price target for Air Products and Chemicals Inc ( APD ) is $325.00, about 26.9% above its November 5 closing price of $237.56

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Roblox Shares Fall Pre-Bell After Hindenburg Research Report
Roblox Shares Fall Pre-Bell After Hindenburg Research Report
Oct 10, 2024
09:25 AM EDT, 10/08/2024 (MT Newswires) -- Roblox ( RBLX ) shares dropped more than 9% in premarket activity Tuesday following a report by short-seller Hindenburg Research. Hindenburg said in its report that Roblox ( RBLX ) allegedly inflated key metrics, such as engagement hours and the number of people on its platform. Roblox ( RBLX ) didn't immediately respond...
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program
Oct 10, 2024
Oct 8 (Reuters) - WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs. ...
What's Going On With Ambow Education Shares Premarket Tuesday?
What's Going On With Ambow Education Shares Premarket Tuesday?
Oct 10, 2024
Ambow Education Holding Ltd. ( AMBO ) shares, which had a tremendous run yesterday, are trading lower premarket today. On Monday, Ambow Education ( AMBO ) entered into a $1.3 million annual renewable licensing agreement with Inspiring Futures Pte. LTD. This non-exclusive deal permits the production and international distribution of the HybriU AI UniBox and the comprehensive HybriU educational solution....
Upstream Bio raises $255 mln in US IPO
Upstream Bio raises $255 mln in US IPO
Oct 10, 2024
Oct 10 (Reuters) - Upstream Bio, which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States. The drug developer joins a swath of biotech companies rushing towards a stock market listing as a long-awaited policy easing cycle begins. September was the busiest month for healthcare...
Copyright 2023-2026 - www.financetom.com All Rights Reserved